Use of palivizumab in primary practice

Pediatrics

Volumn 129, Issue 1, 2012, Pages 55-61

  Perrin, Keith M ^a   Bégué, Rodolfo E ^b  

^a CHILDREN S HOSPITAL   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiolitis; Palivizumab; Primary care; Public health; RSV

Indexed keywords

PALIVIZUMAB;

AGE; ARTICLE; BRONCHIOLITIS; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG COST; DRUG INDICATION; DRUG USE; FEMALE; GESTATIONAL AGE; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATIENT SELECTION; PEDIATRICIAN; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK FACTOR;

EID: 84855268689     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-2991     Document Type: Article

References (20)

1. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118 (4):1774-1793
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446 (Pubitemid 29493797)
3. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183(1):16-22 (Pubitemid 32043037)
4. Koehoorn M, Karr CJ, Demers PA, Lencar C, Tamburic L, Brauer M. Descriptive epidemiological features of bronchiolitis in a population-based cohort. Pediatrics. 2008;122(6):1196-1203
5. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723-1729 (Pubitemid 32578778)
6. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93-99
7. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics. 2010;125(2):342-349
8. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 pt 1):531-537
10. Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540 (Pubitemid 37352516)
11. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211-1216
12. Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 pt 1):1447-1452 (Pubitemid 37523438)
13. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701
14. Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-959, 959.e1
15. Joffe SG, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 pt 1):419-427 (Pubitemid 29424659)
16. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-1619 (Pubitemid 41754927)
17. Meissner HC, Anderson LJ, Pickering LK. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab. Pediatrics. 2004;114(4):1082-1084 (Pubitemid 41529776)
18. Moler FW, Brown RW, Faix RG, Gilsdorf JR. Comments on palivizumab (Synagis). Pediatrics. 1999;103(2):495-497 (Pubitemid 29274549)
19. Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics. 2009;124(6):1682-1684
20. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol. 2010;31(1):90-95